Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT: Phase 3 study of irinotecan liposome injection vs topotecan in small cell lung cancer
2017-004261-26Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2018
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan liposome in small cell lung cancer (SCLC) (2 arms), sponsored by Ipsen. Primary endpoint: Overall survival. Started Feb 2018; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2017-004261-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004261-26.